Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
Skalli
S
S
Wion-Barbot
N
N
Baudrant
M
M
Lablanche
S
S
Benhamou
P Y
PY
Halimi
S
S
D000368:Aged; D000799:Angioedema / Q000139:chemically induced*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077405:Irbesartan; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use
D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D054873:Dipeptidyl-Peptidase IV Inhibitors; D011719:Pyrazines; D013777:Tetrazoles; D014230:Triazoles; D000077405:Irbesartan; D000068900:Sitagliptin Phosphate